Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · February 12, 2015

FOLFOX4 vs Sequential Dose-Dense FOLFOX7 Followed by FOLFIRI in Patients With Resectable Metastatic Colorectal Cancer

Annals of Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Annals of Oncology
FOLFOX4 Versus Sequential Dose-Dense FOLFOX7 Followed by FOLFIRI in Patients With Resectable Metastatic Colorectal Cancer (MIROX): A Pragmatic Approach to Chemotherapy Timing With Perioperative or Postoperative Chemotherapy From an Open-Label, Randomized Phase III Trial
Ann. Oncol 2015 Feb 01;26(2)340-347, M Hebbar, B Chibaudel, T André, L Mineur, D Smith, C Louvet, JL Dutel, M Ychou, JL Legoux, M Mabro, R Faroux, D Auby, D Brusquant, A Khalil, S Truant, A Hadengue, C Dalban, B Gayet, F Paye, FR Pruvot, F Bonnetain, J Taieb, P Brucker, B Landi, M Flesch, E Carola, P Martin, E Vaillant, A de Gramont

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading